Artificial intelligence is pervasive; every major category of technology now incorporates AI techniques and the trend is growing. Although AI offers many benefits, risks and ethical issues abound. Despite having an enormous potential impact on society, jobs, and the economy, policymaking and educational planning have not kept pace with changes in technology, nor are we close to adopting updated legal frameworks. Also: 13 AI trends that will reshape the economy in 2018 TechRepublic Dr. Shirley Malcom is a respected and prominent educator who handles education policy at the American Association for the Advancement of Science (AAAS), which is the world's largest general scientific association and is best known for publishing Science magazine. Among her many honors, Shirley is a Regent of Morgan State University and on the Board of Trustees at Caltech. Education reform and worker re-training in the era of AI are crucial priorities for her.
IBM said Friday it will sell the core data assets of its Watson Health division to a San Francisco-based private equity firm, marking the staggering collapse of its ambitious artificial intelligence effort that failed to live up to its promises to transform everything from drug discovery to cancer care. Data and analytics assets held by the health business, which was not profitable, were sold to Francisco Partners as IBM seeks to refocus its business on cloud computing and AI services to help clients in multiple industries build machine learning tools and secure and manage their data. Terms of the transaction were not disclosed. Unlock this article by subscribing to STAT and enjoy your first 30 days free! STAT is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Corporations today must operate on sound intelligence that comes from every corner and crevice of their business. Information is everywhere, and the ability to extract existing data that cover all details of your operations can give you powerful insights into your people, departments, business units, and even competitors. Taking the proper steps to manage your knowledge equips you with a 360-degree view of your company, giving you a competitive edge and a clear path towards your business goals. Effective knowledge management starts with effective knowledge gathering. This begins with utilizing artificial intelligence (AI) to extract data from unstructured sources to automatically be placed in a single database and converting this data to structured information.
Elon Musk appears close to beginning the first ever human trials of his brain-computer interface technology. A new job posting for a'Clinical Trial Director' at Neuralink reveals that the neurotech startup is preparing to take its brain chip research to the next stage. Neuralink has already conducted trials on pigs and monkeys, including a successful experiment involving a nine-year-old macaque capable of playing video games using only its mind. The firm eventually hopes to use the technology to allow "human-AI symbiosis". Early human trials, which Mr Musk said last month will take place in 2022, will likely involve people with paralysis using Neuralink's interface to gain direct neural control of a computer cursor.
Elon Musk has demonstrated the Neuralink brain chip in a pig, a monkey and we could soon see preform in a human brain. The firm posted a new job listing for a clinical trial director, which says the right candidate will'work closely with some of the most innovative doctors and top engineers, as well as working with Neuralink's first Clinical Trial participants.' The position is based in Fremont, California and provides the candidate with commuter benefits, meals and'an opportunity to change the world.' It also indicates that the job will mean leading and building'the team responsible for enabling Neuralink's clinical research activities,' as well as adhering to regulations. Neuralink posted a new job listing, first spotted by Bloomberg, for a clinical trial director, which says the right candidate will'work closely with some of the most innovative doctors and top engineers, as well as working with Neuralink's first Clinical Trial participants Although the posting does not say when the trials will begin, Musk revealed last month that they are less than a year away - meaning human trials could start this year.
Elon Musk's brain implant company Neuralink is now hiring a clinical trial director, an indication that the company's longstanding goal of implanting chips in human brains is coming closer. The trial director position would oversee the startup's long-promised human trials of its medical device, according to the listing. Neuralink's brain implant -- which Musk has said already allows monkeys to play video games with their thoughts alone -- is intended to help treat a variety of neurological disorders, such as paralysis. The job description for the position, based in Fremont, California, promises that the applicant will "work closely with some of the most innovative doctors and top engineers" as well as with "Neuralink's first Clinical Trial participants." It also indicates that the job will mean leading and building "the team responsible for enabling Neuralink's clinical research activities," as well as adhering to regulations.
The billionaire entrepreneur Elon Musk's brain chip startup is preparing to launch clinical trials in humans. Musk, who co-founded Neuralink in 2016, has promised that the technology "will enable someone with paralysis to use a smartphone with their mind faster than someone using thumbs". The Silicon Valley company, which has already successfully implanted artificial intelligence microchips in the brains of a macaque monkey named Pager and a pig named Gertrude, is now recruiting for a "clinical trial director" to run tests of the technology in humans. "As the clinical trial director, you'll work closely with some of the most innovative doctors and top engineers, as well as working with Neuralink's first clinical trial participants," the advert for the role in Fremont, California, says. "You will lead and help build the team responsible for enabling Neuralink's clinical research activities and developing the regulatory interactions that come with a fast-paced and ever-evolving environment."
Adverse drug events (ADEs), injuries related to drug-related medical interventions, are considered some of the most prevalent types of health-care-related harm. Given that these events are costly and often morbid, artificial intelligence (AI) is considered a promising tool in helping researchers and clinicians understand preventable and novel ADEs, as well as a patient's likelihood of having ADEs before receiving prescription medications. Researchers at Brigham and Women's Hospital conducted a scoping review of 78 articles to identify the key use cases in which AI could be harnessed to prevent or mitigate the effects of ADEs. The review's authors describe the use of AI to reduce the frequency of ADEs as an emerging area of study, and identify several use cases in which AI could contribute to reducing or preventing ADEs. Furthermore, genetic information is thought to be critical in improving the performance of AI algorithms. With the prevalence of genotyping, researchers are confident that this type of data can become more accessible over time, and can ultimately be used to improve AI algorithm functioning and patient health.
You are free to share this article under the Attribution 4.0 International license. Computer algorithms can determine antimicrobial resistance of bacteria faster than previous methods, researchers report. This could help treat serious infections more efficiently in the future. Antibiotic-resistant bacteria are on the rise all over the world. Each year, infections caused by multi-drug resistant bacteria lead to at least 300 fatalities in Switzerland alone.
However, the technology seems to be lagging when it comes to other areas, including translation into drug discovery. Despite a huge amount of media attention for its potential to accelerate this field, AI is yet to be proven as an effective solution. What needs to change for AI to advance drug discovery? AI could make the strongest impact on drug discovery by reducing the number of drugs failing in clinical trials. Currently AI is largely focused on method development using preclinical data – data from research that takes place before human clinical trials – rather than focusing on applying and generating the clinical data we need to make a real impact on drug discovery.